The Effect of Viscous Fiber on Glycemic Control in Individuals With Diabetes

NCT02629263 | Completed

• 1 other identifier: Viscous Fiber and GC
• Study Type: observational
• Target: 1,394
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose of Study (The Effect of Viscous Fiber on Glycemic Control (VF \& GC) in Individuals with Diabetes Mellitus. According to the World Health Organization, about 347 million individuals are living with diabetes. (http://www.who.int/features/factfiles/diabetes/facts/en/, accessed on Nov. 23, 2015). Over the last decades, dietary fibers, namely dietary viscous fibers, have emerged as a nutrition component that may improve the postprandial glycemic response and hence aid in long term diabetes management. It is believed that supplementation with viscous fibers can control blood glucose by increasing viscosity of the gastric digesta, hence delaying gastric emptying and retarding entry of glucose into the bloodstream to result in a diminished postprandial rise in blood glucose. (Chutkan et al., 2012). Currently, the evidence of the relationship between viscous fibers and diabetes is mixed. The systematic review method depends on combining data from many small studies in order to get a pooled estimate of the true effect. The purpose of this study is to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the fasting glycemic and insulinemic effect of viscous fiber supplementation. We hope the findings of this study will play a key role in developing the nutritional guidelines for individuals with diabetes mellitus.

Conditions

Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

• HbA1c (%)

  3 weeks

Secondary Outcomes (4)

• Fasting Blood Glucose (mmol/l)

  ≥ 3 weeks

• Fasting Blood Insulin (pmol/l)

  ≥ 3 weeks

• Fructosamine (mmol/l)

  ≥ 3 weeks

• HOMA-IR (mU/mmol/l)

  ≥ 3 weeks

Interventions

Viscous Fiber DIETARY_SUPPLEMENT

Meta- analysis of Randomized Controlled Trials

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study includes all population types.

You may qualify if:

• Randomized Controlled Trials
• Parallel or Crossover Design
• Duration: ≥ 3 weeks
• Food/ Supplements.
• Soluble Fibers include: B-Glucan, Guar Gum, Konjac, Pectin, Psyllium.
• Diabetes Biomarkers include: Fasting Blood Glucose, Fasting Insulin, Fructosamine, and HbA1c.

You may not qualify if:

• \--------

Sponsors & Collaborators

• Unity Health Toronto: lead

Study Sites (1)

Clinical Nutrition and Risk Factor Modification Centre

Toronto, Ontario, M5C 2T2, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Vladimir Vuksan, PhD

  St.Michael Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2015
• First Posted: December 14, 2015
• Study Start: September 1, 2015
• Primary Completion: May 1, 2019
• Study Completion: May 1, 2019
• Last Updated: October 29, 2019

Record last verified: 2019-10

Locations

CA (1)